FREQUENCY OF EPSTEIN-BARR VIRUS IN CLASSICAL HODGKIN LYMPHOMA
AbstractBackground: Epstein-Barr virus plays an important role in pathogenesis of Hodgkin lymphoma. The first patient with Epstein-Barr positive Reed Sternberg cells was described in 1985. Since then association between Epstein-Barr virus and Hodgkin lymphoma has been shown in many parts of the world and its occurrence shows significant variation from continent to continent and from country to country. Method: The study was carried out at department of histopathology, Armed Forces Institute of Pathology from 27th April 2013 to 10th March 2014. A total of 55 cases of classical Hodgkin lymphoma were included in the study. Results: Out of 55 patients, 38 (69%) were male and 17 (31%) were female. The age of the patients ranged between 4–67 years with an average age of 29.4±21.72 years. Out of these, 44 cases (80%) were positive for latent membrane protein-1. Among positive cases 32 (72.72%) were male and 12 (27.28%) were female. Based upon histological subtypes MCHL was the commonest as a whole accounting for 87.3% as well as among both genders. Out of total 55 cases, 79.16% (38/48) of mixed cellularity Hodgkin lymphoma cases showed positivity for latent membrane protein-1 while 83.33% (5/6) cases of nodular sclerosis Hodgkin lymphoma and 100% (1/1) cases of lymphocyte depleted Hodgkin lymphoma showed positivity. No case of lymphocyte predominant classical Hodgkin lymphoma was diagnosed during the study. 80% of our classical Hodgkin lymphoma cases showed association with EBV expression. A total of 79.16% cases of mixed cellularity Hodgkin lymphoma showed LMP1 expression while 100% of lymphocyte depleted Hodgkin lymphoma showed LMP1 expression. Conclusion: The highest expression seen in lymphocyte depleted Hodgkin lymphoma subtype in contrast to mixed cellularity requires to be confirmed by a larger scale study comprising of substantial number of patients of lymphocyte depleted Hodgkin lymphoma and lymphocyte rich classical Hodgkin lymphoma.Keywords: Hodgkin lymphoma, EBV expression, LMP1.
Brown RE, Nazmi RK. The Reed-Steinberg cell: molecular characterization by proteomic analysis with therapeutic implications. Ann Clin Lab Sci 2002;32(4):339–51.
Gu AD, Zeng MS, Qian CN. The criteria to confirm the role of epstein-barr virus in nasopharyngeal carcinoma initiation. Int J Mol Sci 2012;13(10):13737–47.
Montes-Moreno S, Odqvist L, Diaz-Perez JA, Lopez AB, de Villambrosía SG, Mazorra F, et al. EBV-positive diffuse large B-cell lymphoma of the elderly is an aggressive post-germinal center B-cell neoplasm characterized by prominent nuclear factor-kB activation. Mod Pathol 2012;25(7):968–82.
Nonkwelo C, Skinner J, Bell A, Rickinson A, Sample J. Transcription start sites downstream of the Epstein-Barr virus (EBV) Fp promoter in early-passage Burkitt lymphoma cells define a fourth promoter for expression of the EBV EBNA-1 protein. J Virol 1996;70(1):623–7.
Hohaus S, Santangelo R, Giachelia M, Vannata B, Massini G, Cuccaro A, et al. The viral load of Epstein-Barr virus (EBV) DNA in peripheral blood predicts for biological and clinical characteristics in Hodgkin lymphoma. Clin Cancer Res 2011;17(9):2885–92.
Leonard S, Wei W, Anderton J, Vockerodt M, Rowe M, Murray PG, et al. Epigenetic and transcriptional changes which follow Epstein-Barr virus infection of germinal center B cells and their relevance to the pathogenesis of Hodgkin’s lymphoma. J Virol 2011;85(18):9568–77.
Poppema S. Immunobiology and pathophysiology of Hodgkin lymphomas. Hematology Am Soc Hematol Educ Program 2005;231–8.
Katebi M, Sharifi N, Tarhini M, Otrock ZK, Bazarbachi A, Kchour G. Frequency of Epstein-Barr virus expression in various histological subtypes of Hodgkin’s lymphoma. Histopathology 2008;52(6):775–7.
Koh YW, Yoon DH, Suh C, Huh J. Impact of the Epstein-Barr virus positivity on Hodgkin’s lymphoma in a large cohort from a single institute in Korea. Ann Hematol 2012;91(9):1403–12.
Liu TY, Wu SJ, Huang MH, Lo FY, Tsai MH, Tsai CH, et al. EBV-positive Hodgkin lymphoma is associated with suppression of p21cip1/waf1 and a worse prognosis. Mol Cancer 2010;9:32.
Claviez A, Tiemann M, Lüders H, Krams M, Parwaresch R, Schellong G, et al. Impact of latent Epstein-Barr virus infection on outcome in children and adolescents with Hodgkin’s lymphoma. J Clin Oncol 2005;23(18):4048–56.
Campo E, Swerdlow SH, Harris NL, Pileri S, Stein H, Jaffe ES. The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications. Blood 2011;117(19):5019–32.
Khan G, Norton AJ, Slavin G. Epstein-Barr virus in Hodgkin disease. Relation to age and subtype. Cancer 1993;71(10):3124–9.
De Matteo E, Barón AV, Chabay P, Porta J, Dragosky M, Preciado MV. Comparison of Epstein-Barr virus presence in Hodgkin lymphoma in pediatric versus adult Argentine patients. Arch Pathol Lab Med 2003;127(10):1325–9.
Jarrett RF, Stark GL, White J, Angus B, Alexander FE, Krajewski AS, et al. Impact of tumor Epstein-Barr virus status on presenting features and outcome in age-defined subgroups of patients with classic Hodgkin lymphoma: a population-based study. Blood 2005;106(7):2444–51.
Huang X, Nolte I, Gao Z, Vos H, Hepkema B, Poppema S, et al. Epidemiology of classical hodgkin lymphoma and its association with epstein barr virus in Northern China. PLoS One 2011;6(6):e21152.
Glaser SL, Hsu JL. Hodgkin’s disease in Asians: Incidence patterns and risk factors in population-based data. Leuk Res 2002;26(3):261–9.
MACMAHON B. Epidemiological evidence of the nature of Hodgkin’s disease. Cancer 10(5):1045–54.
Fatima S, Ahmed R, Ahmed A. Hodgkin Lymphoma in Pakistan: An Analysis of Subtypes and their Correlation with Epstein Barr Virus. Asian Pac J Cancer Prev 2011;12(6):1385–8.